RHO and cancer: The possibility that statins impair actin remodeling and/or STRIPAK activity in response to multiple agonists and growth factors that induce Rho activation (ie, conversion of Rho-GDP to Rho-GTP) makes molecular mechanisms intriguing in the context of HCC and other cancers but remains untested.